Canopy Growth Corporation (CGC, Financial) experienced a significant stock price decline of 5.20%. The stock is currently priced at $2.00 per share, with a trading volume of 2.04 million shares and a turnover rate of 1.67%. The price fluctuation amplitude is 3.79%.
Recent financial reports reveal the company generated $46.18 million in revenue but suffered a net loss of $96.45 million, resulting in an earnings per share of -$1.08. The gross profit stood at $11.60 million, with a negative price-to-earnings ratio of -0.43.
In terms of analyst ratings, 11% of the nine participating institutions recommend buying, 44% suggest holding, and 45% advise selling the stock. The pharmaceutical sector, where Canopy Growth operates, saw an overall decline of 0.19%.
Within the sector, stocks like Im Cannabis Corp., Organogenesis Holdings Inc., and Incannex Healthcare Inc. showed notable gains. Meanwhile, stocks such as Cbdmd, Inc. and Painreform Ltd. exhibited high turnover rates of 18.79% and 14.16%, respectively. Stocks with significant price fluctuations included Nature's Sunshine Products, with a 22.54% amplitude, and Zhengye Bio-tech, with a 19.37% amplitude.
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medical and recreational cannabis through brands like Doja, 7ACRES, and Tweed. Its non-THC products include Martha Stewart CBD skincare and Storz & Bickel vaporizers. Canopy's U.S. assets are managed by an independent holding company, Canopy USA, and are not included in the Canadian financial statements.
